Investor Presentaiton
Our journey so far
Foundation
.
Operations started
Expansion of R&D Lab
Granted 100% EOU status
by the Government of India
1993-
2000
Syngene
Globalization and strategic collaboration
•
Expanded into formulations development
•
Contract with Endo Pharmaceuticals to develop novel anti cancer
biological therapeutic molecules
•
Extension of collaboration with BMS;
.
Merger of Clinigene
•
Crossed annual turnover of Rs. 5 Billion
2001-
2009
2010-
2014
Expansion
•
•
Expanded service offerings to
include chemical
development, safety
assessment, biologics
development
Collaboration with BMS to set
up BBRC, Syngene's first
dedicated R&D Center
2015-
2018
IPO and further
collaborations
IPO and listing
Collaboration with
Amgen to set up a
dedicated R&D center
2019 -
2024
Continued investments and
growth
Expanded collaboration with BMS,
Amgen and Zoetis
•
Expansion of IDD platform
•
Laboratory capacity expansion in
Bangalore and Hyderabad
•
•
•
Expansion in Mangalore for
commercial API manufacturing
Capacity and capability addition in
Biologics manufacturing
Entered in long-term partnership
with Zoetis for Biologics
commercial-scale manufacturing
Commissioned sterile fill-finish
facility in Bangalore
Acquired multi-modal biologics
manufacturing facility from Stelis
Biopharma Ltd
Putting Science to Work
8View entire presentation